{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:13:11Z","timestamp":1768720391472,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01532-1","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T12:19:44Z","timestamp":1751113184000},"page":"1255-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetics Model of Thioguanine in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5302-9312","authenticated-orcid":false,"given":"A. B.","family":"Bayoumy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. K. H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. J. J.","family":"Derijks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"2","key":"1532_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17425255.2020.1719996","volume":"16","author":"AB Bayoumy","year":"2020","unstructured":"Bayoumy AB, Simsek M, Seinen ML, et al. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. Expert Opin Drug Metab Toxicol. 2020;16(2):111\u201323. https:\/\/doi.org\/10.1080\/17425255.2020.1719996.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1532_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc2292","volume":"8","author":"P Karran","year":"2008","unstructured":"Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8(1):24\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1532_CR3","doi-asserted-by":"publisher","first-page":"15806","DOI":"10.1038\/s41598-022-20197-5","volume":"12","author":"DS Deben","year":"2022","unstructured":"Deben DS, Creemers RH, van Adrichem AJ, et al. A report on the potential of Rac1\/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients. Sci Rep. 2022;12(1):15806. https:\/\/doi.org\/10.1038\/s41598-022-20197-5.","journal-title":"Sci Rep"},{"issue":"8","key":"1532_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/jci16432","volume":"111","author":"I Tiede","year":"2003","unstructured":"Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133\u201345. https:\/\/doi.org\/10.1172\/jci16432.","journal-title":"J Clin Invest"},{"key":"1532_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329679","author":"NKH de Boer","year":"2023","unstructured":"de Boer NKH, Simsek M, Meijer B, Neurath MF, van Bodegraven A, Mulder CJJ. Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease. Gut. 2023. https:\/\/doi.org\/10.1136\/gutjnl-2023-329679.","journal-title":"Gut"},{"issue":"5","key":"1532_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/ftd.0000000000000869","volume":"43","author":"AB Bayoumy","year":"2021","unstructured":"Bayoumy AB, Mulder CJJ, Loganayagam A, et al. Relationship between thiopurine s-methyltransferase genotype\/phenotype and 6-thioguanine nucleotide levels in 316 patients with inflammatory bowel disease on 6-thioguanine. Ther Drug Monit. 2021;43(5):617\u201323. https:\/\/doi.org\/10.1097\/ftd.0000000000000869.","journal-title":"Ther Drug Monit"},{"key":"1532_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215: 115421. https:\/\/doi.org\/10.1016\/j.addr.2024.115421.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1532_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tips.2024.11.003","volume":"46","author":"AR Bourgonje","year":"2025","unstructured":"Bourgonje AR, Dubinsky MC, Keizer RJ, Dreesen E, Mian P. Model-informed precision dosing in inflammatory bowel diseases. Trends Pharmacol Sci. 2025;46(1):9\u201319. https:\/\/doi.org\/10.1016\/j.tips.2024.11.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1532_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.ftd.0000179839.71138.6d","volume":"28","author":"LJ Derijks","year":"2006","unstructured":"Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit. 2006;28(1):45\u201350. https:\/\/doi.org\/10.1097\/01.ftd.0000179839.71138.6d.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1532_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0378-4347(92)80347-s","volume":"583","author":"L Lennard","year":"1992","unstructured":"Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583(1):83\u201390. https:\/\/doi.org\/10.1016\/0378-4347(92)80347-s.","journal-title":"J Chromatogr"},{"issue":"12","key":"1532_CR11","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1111\/bcp.14360","volume":"86","author":"R Ter Heine","year":"2020","unstructured":"Ter Heine R, Keizer RJ, van Steeg K, et al. Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. Br J Clin Pharmacol. 2020;86(12):2497\u2013506. https:\/\/doi.org\/10.1111\/bcp.14360.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1532_CR12","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/psp4.12684","volume":"10","author":"JH Hughes","year":"2021","unstructured":"Hughes JH, Keizer RJ. A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacometr Syst Pharmacol. 2021;10(10):1150\u201360. https:\/\/doi.org\/10.1002\/psp4.12684.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"6","key":"1532_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1365-2125.2008.03281.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa AF, Collier PS, Millership JS, et al. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2008;66(6):826\u201337. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03281.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1532_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02761","author":"IUS Leong","year":"2024","unstructured":"Leong IUS, Cabrera CP, Cipriani V, et al. Large-scale pharmacogenomics analysis of patients with cancer within the 100,000 genomes project combining whole-genome sequencing and medical records to inform clinical practice. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.23.02761.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1532_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.clpt.2004.07.010","volume":"76","author":"D Soy","year":"2004","unstructured":"Soy D, Beal SL, Sheiner LB. Population one-compartment pharmacokinetic analysis with missing dosage data. Clin Pharmacol Ther. 2004;76(5):441\u201351. https:\/\/doi.org\/10.1016\/j.clpt.2004.07.010.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1532_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","volume":"62","author":"M El Hassani","year":"2023","unstructured":"El Hassani M, Marsot A. External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps. Clin Pharmacokinet. 2023;62(4):533\u201340. https:\/\/doi.org\/10.1007\/s40262-023-01233-7.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1532_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40262-024-01354-7","volume":"63","author":"NC Bevers","year":"2024","unstructured":"Bevers NC, Keizer RJ, Wong DR, et al. Performance of eight infliximab population pharmacokinetic models in a cohort of Dutch children with inflammatory bowel disease. Clin Pharmacokinet. 2024;63(4):529\u201338. https:\/\/doi.org\/10.1007\/s40262-024-01354-7.","journal-title":"Clin Pharmacokinet"},{"key":"1532_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae234","author":"AB Bayoumy","year":"2024","unstructured":"Bayoumy AB, Derijks LJJ, de Boer NKH. DNA-thioguanine (DNA-TG) is a promising novel method to predict adverse events to thiopurine in inflammatory bowel disease. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae234.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1532_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41397-024-00358-7","volume":"24","author":"MJ Deenen","year":"2024","unstructured":"Deenen MJ, van Noordenburg AJ, Bouwens-Bijsterveld J, et al. Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort. Pharmacogenom J. 2024;24(6):39. https:\/\/doi.org\/10.1038\/s41397-024-00358-7.","journal-title":"Pharmacogenom J."},{"issue":"8","key":"1532_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40262-024-01393-0","volume":"63","author":"AB Bayoumy","year":"2024","unstructured":"Bayoumy AB, Ansari AR, Mulder CJJ, Schmiegelow K, Florin T, De Boer NKH. Innovating thiopurine therapeutic drug monitoring: a systematic review and meta-analysis on DNA-thioguanine nucleotides (DNA-TG) as an inclusive biomarker in thiopurine therapy. Clin Pharmacokinet. 2024;63(8):1089\u2013109. https:\/\/doi.org\/10.1007\/s40262-024-01393-0.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1532_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3748\/wjg.v30.i12.1751","volume":"30","author":"T Yang","year":"2024","unstructured":"Yang T, Chao K, Zhu X, et al. Early proactive monitoring of DNA-thioguanine in patients with Crohn\u2019s disease predicts thiopurine-induced late leucopenia in NUDT15\/TPMT normal metabolizers. World J Gastroenterol. 2024;30(12):1751\u201363. https:\/\/doi.org\/10.3748\/wjg.v30.i12.1751.","journal-title":"World J Gastroenterol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01532-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01532-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01532-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:39:48Z","timestamp":1757201988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01532-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01532-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"15 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.B. has\u00a0received a research grant from HLW Pharma (unrestricted)., N.d.B. has served as a speaker for AbbVie and MSD and has served as a consultant and\/or principal investigator for TEVA Pharma BV and Takeda. He has received a research grant (unrestricted) from Dr. Falk, TEVA PharmaBV, Dutch Digestive Foundation (MLDS), and Takeda. L.D. has served as a speaker for AbbVie, Celltrion, Janssen-Cilag, and Takeda and has developed continuing education materials for Ferring, all outside the submitted work. R.J.K. is an employee and stockholder of InsightRX.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data will be made available on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}